[Form 4] Vicarious Surgical Inc. Insider Trading Activity

Rhea-AI Filing Summary

Vicarious Surgical director Beverly A. Huss was reported as receiving a stock option to purchase 5,335 shares of Class A common stock with an exercise price of $7.61. The award is a stock option (right to buy) that will vest on June 27, 2026, or one day prior to the issuer's next annual meeting of shareholders, whichever is earlier, subject to continued service. The option shows an expiration date in mid-2035 and the post-transaction beneficial position is 5,335 options held directly.

Positive

• Aligns director and shareholder interests through equity-based compensation
• Clear time-based vesting schedule (vesting on June 27, 2026, or one day prior to next annual meeting)

Negative

• Potential dilution of 5,335 shares upon exercise of the option
• No performance-based conditions disclosed; vesting is solely time/service-based

Insights

Corporate Governance Expert

TL;DR Routine director stock-option grant with time-based vesting; aligns interests but is not materially transformative.

The filing documents a standard director equity award intended to align management incentives with shareholder value through ownership. The award is time-based with a clear vesting date tied to continued service, which supports retention. Given the size (5,335 options) and lack of performance conditions disclosed, this appears to be a routine compensation action rather than a material corporate governance event.

Compensation Analyst

TL;DR Grant of 5,335 options at $7.61 with a one-year vesting horizon and 2035 expiry; compensation-focused, limited immediate financial impact.

The option grant specifies an exercise price of $7.61 and a vesting schedule that completes on June 27, 2026, subject to service, with an indicated expiration in 2035. From a pay-design perspective, this is a time-vested equity incentive typical for non-employee directors; it creates potential future dilution when exercised but does not immediately change cash flows or reported revenue or expenses in the filing itself.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HUSS BEVERLY A

(Last) (First) (Middle)

C/O VICARIOUS SURGICAL INC.

78 FOURTH AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vicarious Surgical Inc. [ RBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.61	06/27/2025		A		5,335		(1)	06/26/2035	Class A Common Stock	5,335	$0.00	5,335	D

Explanation of Responses:

1. All of the shares underlying this option will vest on June 27, 2026, or one day prior to the Issuer's next Annual Meeting of Shareholders, whichever is earlier, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Erin Checka, Attorney-in-Fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did RBOT report on this Form 4?

A stock option grant for 5,335 shares of Class A common stock with an exercise price of $7.61.

Who is the reporting person on the RBOT Form 4?

The reporting person is director Beverly A. Huss.

When does the option vest for the RBOT grant?

The option vests on June 27, 2026, or one day prior to the issuer's next annual meeting of shareholders, whichever is earlier, subject to continued service.

What is the option expiration date shown in the filing?

The filing indicates an expiration date in mid-2035 (listed as June 26, 2035).

How is ownership reported after the transaction?

The filing reports 5,335 derivative securities beneficially owned directly (D) following the transaction.